MedPacto announces execution of investigator-initiated clinical trials for combination therapy in gastric cancer patients
Apr 11, 2022
Targeting gastric cancer, Vacotsertib in combination with Imfinzi…AstraZenaca Korea will supply Imfinzi
April 11, 2022 – A genome-based drug discovery and clinical-stage biotechnology company, Medpacto announced that it has executed a collaborative study agreement with the National Cancer Center for combination therapy with Vactosertib in recurrent gastric cancer patients.
Dr.HarkKyun Kim at the National Cancer Center will lead this upcoming Phase 2 trial. His research team will test the efficacy and safety of durvalumab in combination with Vactosertib in 55 patients with metastatic and recurrent gastric cancers who have failed ≥3 lines of chemotherapy.
Imfinzi is AstraZeneca’s immune checkpoint inhibitor that blocks the activity of PD-L1 functioning as a disguise that allows cancer cells to go undetected and grow.
MedPacto will supply Vactosertib and AstraZeneca Korea will supply Imfinzi for this trial.
If the trial produces significant clinical results, the pipeline of Vactosertib’s combination therapies targeting gastric cancer will be expanded to two.
MedPacto’s phase 2 clinical trial of Vactosertib’s combination therapy with Paclitaxel targeting gastric cancer is currently underway. This combination therapy has been granted an Orphan Drug Designation from FDA in October 2020.
“As the overall response rates of the immune therapies targeting gastric cancer are significantly low, alternative therapies for gastric cancer are essential.“ stated MedPacto representative. “As the promising results of Vectosertib in combination with other immunotherapies have been released at the several global conferences, we are expecting a significant outcome from a medical perspective.”
MedPacto is currently conducting combination trials with Vactosertib targeting several cancers such as Pancreatic, NSCLC, Bladder, Gastric, Desmoid sarcoma cancer and etc.